Skip to main navigation Skip to search Skip to main content

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

  • Isabelle Bos
  • , Stephanie Vos
  • , Frans Verhey
  • , Philip Scheltens
  • , Charlotte Teunissen
  • , Sebastiaan Engelborghs
  • , Kristel Sleegers
  • , Giovanni Frisoni
  • , Olivier Blin
  • , Jill C. Richardson
  • , R. gis Bordet
  • , Magda Tsolaki
  • , Julius Popp
  • , Gwendoline Peyratout
  • , Pablo Martinez-Lage
  • , Mikel Tainta
  • , Alberto Lleó
  • , Peter Johannsen
  • , Yvonne Freund-Levi
  • , Lutz Frölich
  • Rik Vandenberghe, Sarah Westwood, Valerija Dobricic, Frederik Barkhof, Cristina Legido-Quigley, Lars Bertram, Simon Lovestone, Johannes Streffer, Ulf Andreasson, Kaj Blennow, Henrik Zetterberg, Pieter Jelle Visser
  • Maastricht University
  • Department of Neurology and Memory Clinic, Antwerp, Belgium
  • University of Antwerp
  • Flanders Institute for Biotechnology
  • University of Geneva
  • IRCCS Centro San Giovanni di Dio Fatebenefratelli - Brescia
  • Centre Hospitalo-Universitaire Timone
  • GlaxoSmithKline
  • University of Lille
  • Aristotle University of Thessaloniki
  • University of Lausanne
  • Department of Neurology, San Sebastian, Spain
  • Autonomous University of Barcelona
  • DANBIO
  • Karolinska Institutet
  • Karolinska University Hospital
  • Department of Psychiatry Norrtälje Hospital Tiohundra, Norrtäije, Sweden
  • Ruprecht-Karls-University
  • KU Leuven
  • University of Oxford
  • Universitat zu Lubeck
  • UCL Institute of Neurology
  • Steno Diabetes Center
  • King's College London
  • Imperial College London
  • University of Oslo
  • UCB S.A.
  • University of Gothenburg
  • UK Dementia Research Institute, London, United Kingdom

Research output: Contribution to journalArticleAcademicpeer-review

19 Downloads (Pure)

Abstract

Introduction: We investigated relations between amyloid-β (Aβ) status, apolipoprotein E (APOE) ε4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng), neurofilament light (NFL), YKL-40, and total tau (T-tau). Methods: We included 770 individuals with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD)-type dementia from the EMIF-AD Multimodal Biomarker Discovery study. We tested the association of Ng, NFL, YKL-40, and T-tau with Aβ status (Aβ− vs. Aβ+), clinical diagnosis APOE ε4 carriership, baseline cognition, and change in cognition. Results: Ng and T-tau distinguished between Aβ+ from Aβ− individuals in each clinical group, whereas NFL and YKL-40 were associated with Aβ+ in nondemented individuals only. APOE ε4 carriership did not influence NFL, Ng, and YKL-40 in Aβ+ individuals. NFL was the best predictor of cognitive decline in Aβ+ individuals across the cognitive spectrum. Discussion: Axonal degeneration, synaptic dysfunction, astroglial activation, and altered tau metabolism are involved already in preclinical AD. NFL may be a useful prognostic marker.
Original languageEnglish
Pages (from-to)644-654
Number of pages11
JournalAlzheimer's and Dementia
Volume15
Issue number5
DOIs
Publication statusPublished - 1 May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • APOE
  • Alzheimer's disease
  • Amyloid-β
  • Cerebrospinal fluid
  • Cognition
  • Neurofilament light
  • Neurogranin
  • YKL-40

Fingerprint

Dive into the research topics of 'Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum'. Together they form a unique fingerprint.

Cite this